281 related articles for article (PubMed ID: 27342398)
1. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
2. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
3. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
4. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
5. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.
Zhou XR; Li X; Liao LP; Han J; Huang J; Li JC; Tao HR; Fan SJ; Chen ZF; Li Q; Chen SJ; Ding H; Yang YX; Zhou B; Jiang HL; Chen KX; Zhang YY; Huang CX; Luo C
Acta Pharmacol Sin; 2022 Feb; 43(2):457-469. PubMed ID: 33850273
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Yang S; Zhu Z; Zhang X; Zhang N; Yao Z
Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
8. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
9. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
[TBL] [Abstract][Full Text] [Related]
10. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Tarantelli C; Gaudio E; Arribas AJ; Kwee I; Hillmann P; Rinaldi A; Cascione L; Spriano F; Bernasconi E; Guidetti F; Carrassa L; Pittau RB; Beaufils F; Ritschard R; Rageot D; Sele A; Dossena B; Rossi FM; Zucchetto A; Taborelli M; Gattei V; Rossi D; Stathis A; Stussi G; Broggini M; Wymann MP; Wicki A; Zucca E; Cmiljanovic V; Fabbro D; Bertoni F
Clin Cancer Res; 2018 Jan; 24(1):120-129. PubMed ID: 29066507
[No Abstract] [Full Text] [Related]
11. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
12. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma.
Yue D; Sun X
Cell Death Dis; 2018 Sep; 9(10):935. PubMed ID: 30224718
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
Bashash D; Safaroghli-Azar A; Dadashi M; Safa M; Momeny M; Ghaffari SH
Int J Biochem Cell Biol; 2017 Apr; 85():149-158. PubMed ID: 28254430
[TBL] [Abstract][Full Text] [Related]
14. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
15. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.
Dennison JB; Shanmugam M; Ayres ML; Qian J; Krett NL; Medeiros LJ; Neelapu SS; Rosen ST; Gandhi V
Blood; 2010 Dec; 116(25):5622-30. PubMed ID: 20844237
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
17. Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
Zoellner AK; Bayerl S; Hutter G; Zimmermann Y; Hiddemann W; Dreyling M
Leuk Lymphoma; 2015; 56(12):3393-400. PubMed ID: 26237681
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
Mamidi MK; Mahmud H; Maiti GP; Mendez MT; Fernandes SM; Vesely SK; Holter-Chakrabarty J; Brown JR; Ghosh AK
Leukemia; 2022 Jul; 36(7):1806-1817. PubMed ID: 35568768
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
20. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]